World Smoothened Homolog (Protein Gx or SMO) Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2016" report to their offering.

The report 'Smoothened Homolog - Pipeline Review, H1 2016' outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

'Smoothened Homolog - Pipeline Review, H1 2016'; Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, the author says; Smoothened Homolog (Protein Gx or SMO) Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 3 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Smoothened Homolog (Protein Gx or SMO) Overview
  3. Therapeutics Development
  4. Pipeline Products for Smoothened Homolog (Protein Gx or SMO) - Overview
  5. Pipeline Products for Smoothened Homolog (Protein Gx or SMO) - Comparative Analysis
  6. Smoothened Homolog (Protein Gx or SMO) - Therapeutics under Development by Companies
  7. Smoothened Homolog (Protein Gx or SMO) - Therapeutics under Investigation by Universities/Institutes
  8. Smoothened Homolog (Protein Gx or SMO) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Smoothened Homolog (Protein Gx or SMO) - Products under Development by Companies
  13. Smoothened Homolog (Protein Gx or SMO) - Products under Investigation by Universities/Institutes
  14. Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
  • BeiGene, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Ignyta, Inc.
  • Mayne Pharma Group Limited
  • Novartis AG
  • PellePharm, Inc.
  • Pfizer Inc.
  • Redx Pharma Plc
  • Stemline Therapeutics, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/29r5xk/smoothened

Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716